Why does Alström syndrome vary so much between people?

One of the hardest things for families to understand about Alström syndrome is how different it can look from one person to another. Two people may have the same diagnosis, but one has severe infantile heart disease while another is diagnosed later through vision and metabolic changes. Some lose function quickly in certain systems. Others show a slower pattern. This naturally leads to the question: why does Alström syndrome vary so much between people?

The short answer is that Alström syndrome has marked clinical variability, and current research suggests that the exact genetic variant alone does not fully explain that variability. Even people with the same ALMS1 variant can show different ages of onset, different organ involvement, and different levels of severity. That means other biological and possibly environmental or modifying factors are likely shaping how the disease presents.

The 2024 Frontiers in Pediatrics paper is especially useful here because it focuses directly on this question. The authors presented an infant with dilated cardiomyopathy, above-average weight gain, and later neurosensory deficits who was found to carry a homozygous ALMS1 variant, c.4156dup (p.Thr1386Asnfs*15). They then reviewed the literature to identify all other reported cases with the same variant.

What they found was striking. Even among patients sharing this exact variant, there was high heterogeneity in both the age of onset and the clinical manifestations. The variability persisted even in patients who were homozygous for the same variant. Their conclusion was that genotype-phenotype correlations may not be well supported at the level of specific variants alone.

This matters because families often hope the genetic result will tell them exactly what is going to happen next. That is a very human hope. But in Alström syndrome, the same diagnosis does not guarantee the same course. Even the same variant does not necessarily mean the same timeline or severity. That uncertainty is difficult, but it is also important because it prevents false assumptions.

A child with the same mutation as another reported patient may still follow a different path. That is why families need monitoring based on the individual child in front of them, not only on what happened in someone else’s case.

Variability in Alström syndrome affects both what symptoms appear and when they appear. The 2024 paper describes the syndrome as involving neurosensory deficits, endocrine and metabolic disturbances, cardiomyopathy, and hepatic and renal dysfunction, but not every patient develops every feature in the same way. Age of onset also varies substantially.

For example, one person may present with infantile cardiomyopathy and later develop hearing loss, obesity, and diabetes. Another may first come to attention through visual problems and only later show the broader metabolic picture. Another may have liver and kidney involvement that becomes more obvious over time. The syndrome has a recognisable pattern, but the sequence is far from identical.

ALMS1 clearly causes the syndrome, but the 2024 paper suggests that factors beyond the specific disease-causing allele probably influence how the disease manifests. The authors point out that heterogeneity persisted even in patients with the same homozygous variant, which weakens the argument that one specific mutation location is enough to predict the phenotype with confidence.

This does not mean genetics are unimportant. It means genetics may be necessary for diagnosis without being sufficient for precise forecasting. Other modifier genes, epigenetic influences, tissue-specific responses, developmental timing, or environmental factors may all play a role, even if those mechanisms are not fully mapped yet.

The paper notes that several attempts have been made to establish genotype-phenotype relationships in Alström syndrome, with little success. Many earlier studies looked at broader location-based relationships within the gene, but this case review went further by examining a specific recurrent variant. Even then, clinical heterogeneity remained high.

That is an important finding because it pushes the field away from oversimplified assumptions. It suggests that a clinician should be cautious about telling families that a specific variant automatically means a fixed disease course.

The most practical lesson is not to compare too rigidly. It can be useful to read other families’ experiences or published cases, but those stories should not be treated as exact predictions. A person with Alström syndrome should be monitored according to their own symptoms, test results, and changes over time.

Families can ask good questions such as: what does Alström syndrome look like in this child right now? Which organs are affected already? Which risks are most important at this stage? What does the current heart, hearing, vision, liver, kidney, and metabolic picture show? Those questions are more useful than searching for a perfect one-to-one genetic forecast.

Another important point is that clinical variability should not undermine confidence in the diagnosis itself. Alström syndrome can vary widely and still be clearly Alström syndrome. The diagnosis remains real even when the presentation does not match another family exactly. In fact, variability is one of the known features of the condition.

For some parents, this can actually be reassuring. It means that difference from another case does not automatically mean something is wrong with the diagnosis. It may simply reflect the genuine breadth of the syndrome.